ArticleFrontiers in oncology2026
A multimodal fusion model integrating Vision Transformer, radiomics, and clinical features for predicting bone metastasis in prostate cancer.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To evaluate the performance of a multimodal fusion framework integrating a Vision Transformer (ViT), radiomics, and clinical features for predicting bone metastasis (BM) status in patients with prostate cancer (PCa). Methods: Patients with pathologically confirmed PCa were retrospectively included. Based on clinical features and apparent diffusion coefficient (ADC) images, three single-modal models were constructed: the clinical model (Model_Clin), the radiomics model (Model_Rad), and the ViT model (Model_ViT). Subsequently, a multimodal fusion model (Model_Fusion) was constructed by integrating ViT, radiomics, and clinical features. Model performance was evaluated using the receiver operating characteristic (ROC) curve and the DeLong test. The clinical utility and interpretability of the Model_Fusion were assessed using decision curve analysis (DCA) and Shapley additive explanations (SHAP). Results: Model_ViT demonstrated the best performance among the single-modal models, achieving AUCs of 0.909 and 0.872 in the training and validation sets, respectively, outperforming both Model_Rad (AUC = 0.885 and 0.842) and Model_Clin (AUC = 0.861 and 0.781). By integrating multimodal information, Model_Fusion achieved superior performance (AUC = 0.944 and 0.894). DeLong test results showed that, in the training set, Model_Fusion had a significantly higher AUC than Model_Clin, Model_Rad, and Model_ViT (all Conclusion: A fusion model integrating ViT, radiomics, and clinical features provides a non-invasive framework for predicting BM in PCa, which may help guide personalized clinical decision-making and prognostic evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.